ALCAFTADINE Struktur

ALCAFTADINE

Bezeichnung:ALCAFTADINE

CAS-Nr147084-10-4

Englisch Name:ALCAFTADINE

CBNumberCB21011726

SummenformelC19H21N3O

Molgewicht307.39

MOL-Datei147084-10-4.mol

ALCAFTADINE physikalisch-chemischer Eigenschaften

Schmelzpunkt	167 °C
Siedepunkt	556.2±60.0 °C(Predicted)
Dichte	1.24
storage temp.	Inert atmosphere,Store in freezer, under -20°C
Löslichkeit	DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/ml
Aggregatzustand	powder to crystal
pka	8.76±0.20(Predicted)
Farbe	White to Yellow to Orange

Sicherheit

HS Code

2933.39.4100

Gefahreninformationscode (GHS)

Bildanzeige (GHS)
Alarmwort

Warnung
Gefahrenhinweise

H315：Verursacht Hautreizungen.

H319：Verursacht schwere Augenreizung.

H335：Kann die Atemwege reizen.
Sicherheit

P261：Einatmen von Staub vermeiden.

P264：Nach Gebrauch gründlich waschen.

P264：Nach Gebrauch gründlich waschen.

P271：Nur im Freien oder in gut belüfteten Räumen verwenden.

P280：Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.

P302+P352：BEI BERÜHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckmäßig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.

P304+P340：BEI EINATMEN: Die Person an die frische Luft bringen und für ungehinderte Atmung sorgen.

P305+P351+P338：BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen.

P312：Bei Unwohlsein GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

P321：Besondere Behandlung

P332+P313：Bei Hautreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

P337+P313：Bei anhaltender Augenreizung: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen.

P403+P233：An einem gut belüfteten Ort aufbewahren. Behälter dicht verschlossen halten.

P405：Unter Verschluss aufbewahren.

P501：Inhalt/Behälter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

ALCAFTADINE Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Alcaftadine, a histamine H₁/H₂ receptor antagonist, was approved in the United States in 2010 for the prevention of itching and redness associated with allergic conjunctivitis. Seasonal and perennial allergic conjunctivitis affects up to 40% of the population worldwide. There are numerous treatment options, with topical antihistamines being an effective therapy. Some of the primary symptoms and signs of allergic conjunctivitis are ocular itching and conjunctival redness. The pharmaceutical market for conjunctivitis is substantial and steadily increasing.
Originator
Janssen Research Foundation (United States)
Verwenden
Alcaftadine is a H1 histamine receptor antagonist. Alcaftadine is used to prevent eye irritation and treat the signs and symptoms of allergic conjunctivitis.
Definition
ChEBI: An imidazobenzazepine that is 6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine substituted at position 3 by a formyl group and at position 11 by a 1-methylpiperidin-4-ylidene group. An antihistamine used for treatment of allergi conjunctivitis.
Trademarks
LastacaftTM
Clinical Use
Alcaftadine, an ophthalmic histamine H1 receptor antagonist, was approved by the FDA for the prevention of itching associated with allergic conjunctivitis and was launched under the trade name Lastacaft in early 2011. Alcaftadine was discovered by Janssen Pharmaceuticals and marketed by Vistakon Pharmaceuticals, both subsidiaries of Johnson & Johnson. However, unlike other marketed drugs, the synthesis of alcaftadine was only mentioned in the patents filed by Janssen’s scientists approximately twenty years ago.
Synthese
The synthetic route described in the scheme is based on the discovery route disclosed in those patents. 1-(2-Phenylethyl)- 1H-imidazole 7 is now commercially available, otherwise it could be prepared by reacting imidazole (5) with 2-phenylethyl bromide (6). With pyridine and triethylamine as base, imidazole 7 was reacted with acyl chloride 8 to provide piperidinecarboxylate 9 in 34% yield, followed by acid hydrolysis with 48% HBr aqueous solution to obtain piperidine dihydrobromide 10 in 98% yield. The N-methylation of 10 was acheived by Leuckart reaction with formaldehyde and formic acid to give 4-methylpiperidine 11 in 82% yield. Treatment of 11 with trifluoromethanesulfonic acid followed by subsequent basification triggered an intramolecular alkylation¨Cdehydration reaction to generate benzazepine 12. Next, alcohol 13 was obtained by prolonged exposure (7 days) of 12 to hydroxymethylation conditions using 40% aqueous formaldehyde. Oxidation of 13 with manganese (IV) oxide provided alcaftadine (II). The yields of last three steps from compound 11 to alcaftadine (II) were not provided in the patent.

ALCAFTADINE Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

147084-10-4, ALCAFTADINE Verwandte Suche:

Send Inquriy